Sandrine Hiret

Publication Activity (10 Years)

Years Active: 2018-2022
Publications (10 Years): 2

Top Topics

Acute Lymphoblastic Leukemia

Diffuse Large B Cell Lymphoma

Angiotensin Converting Enzyme

Top Venues

Cancer discovery

Investigational new drugs

This page only lists publications with an associated author ORCID identifier.

Publications

Benoit Rousseau, Ivan Bièche, Éric Pasmant, Nadim Hamzaoui, Nicolas Leulliot, Lucas Michon, Aurélien de Reyniès, Valerie Attignon, Michael B Foote, Julien Masliah-Planchon, Magali Svrcek, Romain Cohen, Victor Simmet, Paule Augereau, David Malka, Antoine Hollebecque, Damien Pouessel, Carlos Alberto Gomez Roca, Rosine Guimbaud, Amandine Bruyas, Marielle Guillet, Jean-Jacques Grob, Muriel Duluc, Sophie Cousin, Christelle De La Fouchardière, Aude Flechon, Frédéric Rolland, Sandrine Hiret, Esma Saada-Bouzid, Olivier Bouche, Thierry André, Diane Pannier, Farid El Hajbi, Stephane Marie Oudard, Christophe Tournigand, Jean-Charles Soria, Stephane Champiat, Drew G Gerber, Dennis Stephens, Michelle F Lamendola-Essel, Steven B Maron, Bill H Diplas, Guillem Argilés, Asha R Krishnan, Séverine Tabone-Eglinger, Anthony Ferrari, Neil H Segal, Andrea Cercek, Natalie Hoog-Labouret, Frederic Legrand, Clotilde Simon, Assia Lamrani-Ghaouti, Luis A Diaz, Pierre Saintigny, Sylvie Chevret, Aurélien Marabelle
PD-1 Blockade in Solid Tumors with Defects in Polymerase Epsilon. Cancer discovery 12 (6) (2022)
Sandrine Hiret, Nicolas Isambert, Carlos Gomez-Roca, Jaafar Bennouna, Mouna Sassi, Hélène de Mont-Serrat, Jean Fan, David Schnell, Jean-Pierre Delord
Phase I dose-escalation trial of afatinib, an irreversible ErbB family blocker, in combination with gemcitabine or docetaxel in patients with relapsed or refractory solid tumors. Investigational new drugs 36 (6) (2018)